18343-02-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 3-(2-ethoxy-2-oxoethoxy)isonicotinate is used as an intermediate in the synthesis of pharmaceuticals for its potential therapeutic effects and ability to inhibit the growth of harmful microorganisms.
Used in Agrochemicals:
Ethyl 3-(2-ethoxy-2-oxoethoxy)isonicotinate is used as an intermediate in the synthesis of agrochemicals, contributing to the development of effective products for agricultural applications.
Used in Medicinal Chemistry:
Ethyl 3-(2-ethoxy-2-oxoethoxy)isonicotinate is used as a building block in the production of various drugs, playing a crucial role in the advancement of medicinal chemistry.

Upstream product

• 18342-97-7 ethyl 3-hydroxyisonicotinate 
• 105-36-2 ethyl bromoacetate 
• 623-50-7 ethyl 2-hydroxyacetate 
• 10128-71-9 3-hydroxyisonicotinic acid 
• 141-78-6 ethyl acetate 

Downstream Products

• 106531-50-4 Ethyl 3-Hydroxyfuro<2,3-c>pyridine-2-carboxylate 
• 19539-50-5 furo<2,3-c>pyridine 
• 106531-53-7 2,3-Dihydrofuro<2,3-c>pyridin-3-ol 
• 106531-51-5 Furo<2,3-c>pyridin-3(2H)-one hydrochloride 
• 1453175-37-5 furo[2,3-c]pyridine-2-carboxylic acid 4-(1-isobutylpiperidine-4-sulfinyl)benzylamide 
• 1453173-84-6 N-[(4-tetrahydropyran-4-ylsulfonylphenyl)methyl]furo[2,3-c]pyridine-2-carboxamide 
• 927804-63-5 ethyl 3-(((trifluoromethyl) sulfonyl)oxy)furo[2,3-c]pyridine-2-carboxylate 
• 138173-83-8 Ethyl furo<2,3-c>pyridine-2-carboxylate 
• 112372-15-3 furo<2,3-c>pyridine-2-carboxylic acid 
• 1453174-07-6 N-[[4-[(1-tetrahydropyran-4-yl-4-piperidyl)sulfonyl]phenyl]methyl]furo[2,3-c]pyridine-2-carboxamide 
• 465531-08-2 furo[2,3-c]pyridine-2-carbonyl chloride 
• 1453176-78-7 furo[2,3-c]pyridine-2-carboxylic acid benzylamide 
• 1453176-79-8 4-{[(furo[2,3-c]pyridine-2-carbonyl)-amino]-methyl}-benzenesulfonyl chloride 
• 1453175-46-6 C₂₄H₂₉N₃O₃S 

Relevant academic research and scientific papers

AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

AMIDO-BENZYL SULFONE AND SULFONAMIDE DERIVATIVES

Disclosed are certain amido-benzyl sulfone and sulfonamide compounds, pharmaceutical compositions comprising such compounds, land methods of treatment using such compounds.

ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES

The present invention relates to certain alkyl- and di-substituted amido-benzyl sulfonamide compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment of NAMPT-mediated disorders, such as diabetes, rheumatoid arthritis,

The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors

Virtual and high-throughput screening identified imidazo[1,2-a]pyrazines as inhibitors of B-Raf. We describe the rationale, SAR, and evolution of the initial hits to a series of furo[2,3-c]pyridine indanone oximes as highly potent and selective inhibitors

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE

The invention relates to azabenzofuranyl compounds of Formula (I) with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Raf inhibitor compounds and methods of use thereof

Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Furopyridines. V. A Simple Synthesis of Furopyridine and Its 2- and 3-Methyl Derivatives

A simple synthesis of furopyridine and its 2- and 3-methyl derivatives from ethyl 3-hydroxyisonicotinate (2) is described.The hydroxy ester 2 was O-alkylated with ethyl bromoacetate or ethyl 2-bromopropionate to give the diester 3a or 3b.Cyclization of compound 3a afforded ethyl 3-hydroxyfuropyridine-2-carboxylate (4) which was hydrolyzed and decarboxylated to give furopyridin-3(2H)-one (5a).Cyclization of 3b gave the 2-methyl derivative 5b.Reduction of 5a and 5b with sodium borohydride yielded the corresponding hydroxy derivative 6a and 6b, respectively, which were dehydrated with phosphoric acid to give furopyridine (7a) and its 2-methyl derivative 7b. 4-Acetylpyridin-3-ol (8) was O-alkylated with ethyl bromoacetate to give ethyl 2-(4-acetyl-3-pyridyloxy)acetate (9).Saponification of compound 9, and the subsequent intramolecular Perkin reaction gave 3-methylfuropyridine (10).Cyclization of 9 with sodium ethoxide gave 3-methylfuropyridine-2-carboxylic acid, which in turn was decarboxylated to give compound 10.